This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Irwin, J. C. Articles by Giudice, L. C. Search for Related Content PubMed PubMed Citation Articles by Irwin, J. C. Articles by Giudice, L. C. Pubmed/NCBI databases Medline Plus Health Information Pregnancy

Human Placental Trophoblasts Secrete a Disintegrin Metalloproteinase Very Similar to the Insulin-Like Growth Factor Binding Protein-3 Protease in Human Pregnancy Serum¹

Department of Gynecology and Obstetrics (J.C.I., L.-F.S., L.C.G.), Stanford University Medical Center, Stanford, California 94305-5317; Department Obstetrics & Gynecology (B.-H.C.), Kaohsiung Medical College Hospital, 80708 Taiwan; Roche Bioscience (R.M., P.C.), Palo Alto, California 94304; and Department of Pediatrics (C.L.D.), Hôpital Sainte-Justine, Montréal, Québec, H3T 1CS Canada

Address all correspondence and requests for reprints to: Linda C. Giudice, M.D., Ph.D., Department of Gynecology & Obstetrics, Stanford University Medical Center, Stanford, California 94305-5317. E-mail: giudice{at}stanford.edu

During the course of human pregnancy, there is a marked increase in insulin-like growth factor (IGF) binding protein (IGFBP)-3 protease activity in maternal serum that is first evident at 6 weeks of gestation, persists through term, and returns to nonpregnancy levels by day 5 postpartum. This protease activity cleaves IGFBP-3 into smaller fragments that have markedly reduced affinity for the IGFs. To date, the precise identity and cellular origin of the pregnancy-associated serum IGFBP-3 protease have not been established. To investigate whether placental and/or decidual tissues, which uniquely develop during pregnancy, may be sources of the pregnancy-associated serum IGFBP protease, we examined the secretion of IGFBP-3 protease in vitro by isolated human cytotrophoblasts or fibroblasts from second trimester placentae and by in vitro decidualized human endometrial stromal cells. Cytotrophoblasts were either cultured alone, which favors aggregation and fusion, or cocultured with decidualized endometrial stromal cells, which favors differentiation to an invasive phenotype. IGFBP-3 protease activity was detected in trophoblast, but not in placental fibroblast or decidualized endometrial cultures, and was also present in trophoblast-endometrial cocultures. Western ligand blot and Western immunoblot analyses showed that most of the endogenous IGFBP-3 in trophoblast cultures was in the form of low molecular weight fragments with reduced IGF binding affinity. The substrate specificity of the trophoblast-derived protease was identical to that in pregnancy serum, showing activity against IGFBP-2, -3, and -4, but being inactive against IGFBP-1. IGFBP-3 proteolysis by both pregnancy serum and trophoblast conditioned medium showed a major peak of activity at neutral pH. The trophoblast-derived activity caused time- and temperature-dependent proteolysis of IGFBP-3 into fragments of identical size as those produced by pregnancy serum, and also shared its sensitivity to protease inhibitors: highly sensitive to EDTA and o-phenanthroline, partially sensitive to the serine protease inhibitors AEBSF and aprotinin, and insensitive to ₂-antiplasmin, and to aspartic and cysteine protease inhibitors. IGFBP-3 proteolysis by both pregnancy serum and trophoblast conditioned medium was also insensitive to tissue inhibitor of metalloproteinase-1, precluding the involvement of the matrix metalloproteinases. In contrast, both the pregnancy serum- and trophoblast-derived proteases were preferentially inhibited by a hydroxamic acid derivative with selective activity against the disintegrin-metalloproteinase tumor necrosis factor- converting enzyme. This study shows that placental trophoblasts produce an IGFBP-3 protease with characteristics very similar to the activity found in pregnancy serum and indicates these cells at the maternal-fetal interface are a potential source of the pregnancy-associated serum IGFBP-3 protease. The findings further suggest that the main IGFBP-3 protease activity in both pregnancy serum and trophoblast conditioned medium may correspond to a disintegrin-metalloproteinase type enzyme.

This article has been cited by other articles:

				S. Jogie-Brahim, D. Feldman, and Y. Oh Unraveling Insulin-Like Growth Factor Binding Protein-3 Actions in Human Disease Endocr. Rev., August 1, 2009; 30(5): 417 - 437. [Abstract] [Full Text] [PDF]

				H. P. Sorensen, R. R. Vives, C. Manetopoulos, R. Albrechtsen, M. C. Lydolph, J. Jacobsen, J. R. Couchman, and U. M. Wewer Heparan Sulfate Regulates ADAM12 through a Molecular Switch Mechanism J. Biol. Chem., November 14, 2008; 283(46): 31920 - 31932. [Abstract] [Full Text] [PDF]

				H. A. Coppock, A. White, J. D. Aplin, and M. Westwood Matrix Metalloprotease-3 and -9 Proteolyze Insulin-Like Growth Factor-Binding Protein-1 Biol Reprod, August 1, 2004; 71(2): 438 - 443. [Abstract] [Full Text] [PDF]

				L. C. Giudice, C. A. Conover, L. Bale, G. H. Faessen, K. Ilg, I. Sun, B. Imani, L.-F. Suen, J. C. Irwin, M. Christiansen, et al. Identification and Regulation of the IGFBP-4 Protease and Its Physiological Inhibitor in Human Trophoblasts and Endometrial Stroma: Evidence for Paracrine Regulation of IGF-II Bioavailability in the Placental Bed during Human Implantation J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2359 - 2366. [Abstract] [Full Text] [PDF]

				L. Shalamanova, B. Kubler, J.-G. Scharf, and T. Braulke MDCK cells secrete neutral proteases cleaving insulin-like growth factor-binding protein-2 to -6 Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1221 - E1229. [Abstract] [Full Text] [PDF]

				C. LASSARRE and M. BINOUX Measurement of Intact Insulin-Like Growth Factor-Binding Protein-3 in Human Plasma Using a Ligand Immunofunctional Assay J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1260 - 1266. [Abstract] [Full Text]

				D. Byun, S. Mohan, M. Yoo, C. Sexton, D. J. Baylink, and X. Qin Pregnancy-Associated Plasma Protein-A Accounts for the Insulin-Like Growth Factor (IGF)-Binding Protein-4 (IGFBP-4) Proteolytic Activity in Human Pregnancy Serum and Enhances the Mitogenic Activity of IGF by Degrading IGFBP-4 in Vitro J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 847 - 854. [Abstract] [Full Text]

				J.M. Gibson, J.D. Aplin, A. White, and M. Westwood Regulation of IGF bioavailability in pregnancy Mol. Hum. Reprod., January 1, 2001; 7(1): 79 - 87. [Abstract] [Full Text] [PDF]

				Z. Shi, W. Xu, F. Loechel, U. M. Wewer, and L. J. Murphy ADAM 12, a Disintegrin Metalloprotease, Interacts with Insulin-like Growth Factor-binding Protein-3 J. Biol. Chem., June 9, 2000; 275(24): 18574 - 18580. [Abstract] [Full Text] [PDF]